Skip to main content

Foehr Matthew W's Form 4 filing

Ligand Pharmaceuticals Inc (LGND) · filed Aug 5, 2021

Accession no.
0000886163-21-000121
Filed
Aug 5, 2021
Trade date
Aug 4, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $969.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Foehr Matthew WCIK 0001237556Officer (President and COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 4, 2021Common StockMOption exerciseAcquired+8,840$21.92+$193,772.8173,195Direct
Aug 4, 2021Common StockSSaleDisposed−8,840$109.67F1−$969,482.8164,355Direct
Aug 4, 2021Common StockMOption exerciseAcquired+1,142$85.79+$97,972.18165,497Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 4, 2021Common StockMOption exerciseDisposed−8,840$0.00$011,160Direct
Aug 4, 2021Common StockMOption exerciseDisposed−1,142$0.00$025,938Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.06 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)